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AbstrAct
The WHO launched a Global Action Plan on antimicrobial 
resistance (AMR) in 2015. World leaders in the G7, G20 
and the UN General Assembly have declared AMR to be a 
global crisis. World leaders have also adopted universal 
health coverage (UHC) as a key target under the 
sustainable development goals. This paper argues that 
neither initiative is likely to succeed in isolation from 
the other and that the policy goals should be to both 
provide access to appropriate antimicrobial treatment 
and reduce the risk of the emergence and spread of 
resistance by taking a systems approach. It focuses on 
outpatient treatment of human infections and identifies a 
number of interventions that would be needed to achieve 
these policy goals. It then shows how a strategy for 
achieving key attributes of a health system for UHC can 
take into account the need to address AMR as part of a 
UHC strategy in any country. It concludes with a list of 
recommended priority actions for integrating initiatives 
on AMR and UHC.
IntroductIon
In 2015, the WHO launched a Global 
Action Plan on antimicrobial resistance 
(AMR) to address a challenge, which its 
director general characterised as: ‘threat-
ening the very core of modern medicine and the 
sustainability of an effective global public health 
response to the enduring threat of infectious 
diseases’.1 The emergence and spread of 
pathogens resistant to antimicrobials poses 
a big challenge to policy makers, who need 
to oversee the transformation of health 
systems that evolved to provide easy access 
to these drugs into ones that provide access 
to appropriate antimicrobial treatment while 
reducing the risk of the emergence and spread 
of resistance. They also need to persuade 
health workers, producers and distributors 
of antimicrobials and the general public 
that the right of access to the benefits of 
antimicrobials needs to be complemented 
by responsibility for preserving their effi-
cacy.
There is a broad scientific consensus on 
the magnitude of the challenge to the effi-
cacy of existing antimicrobial drugs.2 3 A 
number of pathogenic organisms have been 
found to be resistant to a variety of anti-
microbial agents in a number of countries 
around the world.4 Several authors have 
explored the likely impact on avoidable sick-
ness and death, increased cost of treatment 
of infections and lost income and wealth.3 5 6 
A recent World Bank estimate suggests that 
global domestic product per annum will be 
decreased by between 1.1% and 3.8% by 
2050, if AMR remains unchecked and that 
an investment of US$9 billion per year will 
be needed to avoid this outcome.7 In this 
paper, we argue that some of this investment 
should be spent on building the capacity of 
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Key questions
What is already known about this topic?
 ► The WHO and world leaders are giving high priority 
to initiatives to make progress towards universal 
health coverage (UHC) and to address the challenge 
of AMR.
 ► In many health systems, widespread 
inappropriate use of antimicrobials is combined 
with inadequate access to them, especially for 
the poor.
 ► Health system strengthening efforts have tended to 
neglect measures to ensure access to appropriate 
antibiotic treatment of infections.
What are the new findings?
 ► An effective strategy for addressing antimicrobial 
resistance (AMR) needs to both ensure access to 
effective therapy for common infections and reduce 
the risk of emergence of resistance.
 ► A systems framework for UHC is necessary to 
work across the continuum from prevention to 
care and to address the many factors that lead 
to AMR.
recommendations for policy
 ► It is important to understand the linkage between 
the two priorities and ensure that the use of 
antimicrobials is both just and sustainable.
 ► Action is needed at national and global levels to 
ensure there is an integrated approach for making 
progress towards UHC and for addressing AMR.
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Figure 1 A complex system: human drivers of antibiotic resistance in pluralistic health system. Source: Antimicrobial 
resistance in the Asia Pacific region: a development agenda. Geneva: World Health Organization, 2017.
health systems to provide access to effective treatment 
of common infections while reducing the risk of AMR.
unIversAl HeAltH coverAge (uHc) And AMr
The WHO is leading two health initiatives with big impli-
cations for the use of antimicrobials. First, Sustainable 
Development Goal 3 includes a commitment to achieve 
UHC by the year 2030. This implies significant increases 
in access to healthcare, including treatment of infec-
tions. Second, the Global Action Plan on AMR aims at 
‘ensuring, for as long as possible, continuity of successful 
treatment and prevention of infectious diseases with 
effective and safe medicines that are quality assured, 
used in a responsible way and accessible to all who need 
them’.1 Neither initiative is likely to succeed in isolation 
from the other. Action to address AMR should go hand 
in hand with measures to strengthen attributes of health 
systems that contribute to progress towards UHC such 
as: equity, quality, efficiency, accountability, sustainability 
and resilience. This paper explores the ways that efforts 
to both make progress towards UHC and delay the emer-
gence and spread of AMR are interconnected. It focuses 
on the use of antimicrobials for outpatient treatment.
A number of global statements have recognised the 
need to address the many routes of contact between 
micro-organisms and antibiotics including through 
ingestion by humans and animals and leakage into the 
environment.8–11 A recent WHO publication incorpo-
rates this understanding into a regional action plan 
for the Western Pacific Region.12 Figure 1 focuses only 
on the drivers of human antibiotic use. It takes into 
account the widespread existence of pluralistic health 
systems, which include a mix of providers of health-
care and drugs in terms of their ownership and their 
relationship to the regulatory system.13 Access to and 
use of antibiotics in such a system involves interactions 
between technical dimensions, such as availability of 
treatment guidelines, low cost diagnostic technologies 
and good quality drugs, behavioural dimensions, such 
as knowledge, incentives and cultural beliefs, and the 
influence of a wide range of actors including healthcare 
practitioners, drug companies, medical schools and 
regulatory agencies.
National governments and key stakeholders can under-
take a number of actions to integrate AMR and UHC. 
Some priority actions for low-income and middle-income 
countries with relatively weak drug management and 
regulatory arrangements could include the following:
Prevention
 ► Improvements in basic public health and disease pre-
vention.
Access and responsible use
 ► Improved access to appropriate and affordable treat-
ment of infections, especially for the poor through 
enactment and enforcement of regulations, dissem-
ination of treatment guidelines based on AMR sur-
veillance data, along with awareness raising on the 
responsible use of antimicrobials and the challenge 
of AMR.
Financial incentives
 ► Realignment of incentives within drug value chains 
and delinking health worker income from the vol-
ume of antimicrobial drugs supplied.
 ► Measures to reduce financial barriers to access to an-
timicrobial treatment of infections, linked with meas-
ures to encourage judicious use of these drugs.
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Institutional arrangements and partnerships
 ► Strengthening the capacity of governments to play 
a role as regulator and steward of the health system, 
incorporating oversight of the private and informal 
sector.
 ► Creation of partnerships, across the plurality of pro-
viders of drugs and information, that foster shared 
visions, interests and commitments.
These actions are described in more detail below.
Prevention and population level action to decrease the burden of 
infections
The risk of emergence and subsequent transmission of 
AMR genes can be reduced by immunising the popula-
tion against common infectious diseases and measures 
to reduce exposure to infections through contaminated 
water and food and reduce the susceptibility of people to 
infections by improving nutrition and treating conditions 
such as HIV infection. It is important that UHC strategies 
take this into account.
Ensuring access to effective and appropriate treatment of 
infections
In countries with a pluralistic health system, it is typical 
for people to seek treatment for a large proportion of 
common infections in weakly regulated markets.13 These 
arrangements have enabled people to obtain treatment 
for many infections and reduce mortality. However, there 
are problems with the use of substandard drugs, taking 
partial courses of treatment and overuse of antimicro-
bials. The simultaneous existence of insufficient access to 
safe, effective and affordable treatment of common infec-
tions and high levels of inappropriate use of antibiotics 
creates special challenges for government action.14
Enacting and enforcing laws that reserve the right 
to prescribe antibiotics to licenced healthcare workers 
may not be realistic in many pluralistic health systems, 
where governments face a choice between denying 
many people access to life-saving drugs and turning a 
blind eye to nominally illegal practices. An alternative 
is for governments to strengthen their role as regulator 
and steward of the health sector and act to improve the 
performance of informal health workers and drug sellers 
in providing antibiotic treatment of common infections. 
This will require a combination of measures to ensure 
drug quality, encourage the use of treatment guidelines 
and alter incentives that encourage excessive use of 
antimicrobials.
Ensuring access to reliable information and advice
Health workers, drug sellers and the general public make 
decisions about when and how to use antimicrobials in a 
complex health knowledge economy.15 The boundaries 
between information consumed by providers and the 
public are blurred: healthcare worker training institutes 
teach about the use of these drugs; government health 
services issue public health messages and organise special 
programmes, which sometimes recommend treatment 
without a specific diagnosis; companies that produce 
or distribute drugs provide information and advice to 
healthcare workers and drug sellers; advertising compa-
nies seek to influence the general public through the 
mass media; and the internet and mobile phones have 
become important sources of health information and 
advice for patients and providers. Government regu-
lators, organised professions and industry associations 
issue guidelines and standards.
Until recently, all these sources have emphasised the 
efficacy of antimicrobials in treating sickness and saving 
lives. The emphasis of policy debates has been on the 
right of access to these drugs. Antibiotics have devel-
oped a reputation for being ‘strong’ medicines with the 
capacity to cure a range of ailments.16 Patients expect 
to have access to these drugs. Health workers use anti-
biotics for any possible indication of infection and risk 
being accused of missing an infection if they deviate 
from this practice. Efforts to limit the use of antibiotics 
have to contend with these ingrained beliefs, norms and 
entitlements.
A number of measures will be needed to align the 
knowledge economy with current and emerging scien-
tific knowledge. Strategies are needed to educate and 
support healthcare providers in responsible prescribing. 
For example, guidelines could be developed for treating 
common infections, taking prevalent patterns of AMR 
into account. These guidelines could be incorporated 
into training courses and supplied to formal and informal 
providers of health advice and drugs. Strategies to raise 
awareness and reduce consumer demand for antimicro-
bials is also needed. The general public should be given 
basic information on when to use antimicrobials. Two 
important sources of information on antimicrobials are 
the publications that pharmaceutical companies produce 
and advertising on the mass media and social media. 
Voluntary standards and/or government regulations 
will be needed to provide impartial advice on the use of 
antimicrobials.
Management of supply chains for antimicrobials
The organisation of the production, distribution and 
supply of antimicrobials to patients strongly influences 
the way people use these products. In many coun-
tries, there are serious problems with counterfeit and 
substandard products. The packaging of antimicrobials 
influences the way they are taken. For example, it would 
be possible to produce combination therapy products 
and package them in full courses of treatment.
Drug wholesalers influence the people to whom they 
supply by providing information and advice and offering 
financial incentives to encourage a high volume of sales.17 
The influence of pharmaceutical marketing is consider-
able. Strategies to reduce the provision of misleading 
information and perverse incentives throughout the 
supply chain are needed. They need to involve govern-
ment and private companies.18 Governments need to 
set basic quality standards for drugs. They may also set 
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standards concerning treatment guidelines and the 
contents of promotional and advertising material. Effec-
tive interventions need the involvement of the pharma-
ceutical sector and leaders of the medical profession to 
encourage adherence to agreed regulations and profes-
sional and industry quality standards.
Guidelines to promote responsible use
The international community has supported a number 
of initiatives to promote treatment of infections where 
people do not have easy access to a medical doctor. They 
have typically employed a syndromic approach, in which 
people with symptoms of an infection are treated with 
an antibiotic without a definitive diagnosis. Some initi-
atives have advocated prophylactic use of antibiotics by 
high-risk groups, such as sex workers. These initiatives 
have contributed to the now widespread public percep-
tion of the efficacy and strength of antimicrobials and to 
the high level of demand for them. The problem of AMR 
raises questions about these strategies.
The alternative is to develop practical approaches for 
diagnosing and offering specific treatment for infections. 
New low-cost diagnostic tests are needed that can iden-
tify a specific pathogen or, at a minimum, distinguish 
between bacterial and viral infections. This could be 
linked to the development of appropriate ways of organ-
ising their use in countries without high levels of access 
to the formal healthcare system.19 There are significant 
challenges to the development, regulatory approval and 
clinical integration of diagnostic tests that use new tech-
nologies. It will probably involve collaboration between 
private, non-profit and academic institutions.
Research is needed to establish appropriate treat-
ment guidelines for common infections in a context of 
changing patterns of AMR. These guidelines need to be 
updated based on the dynamics of antibiotic usage and 
evidence of emerging resistance.20 Promotion of sequen-
tial use, cycling strategies or mixing strategies of different 
antibiotics have all demonstrated positive effects on the 
reduction of AMR.21 There is also a need to look more 
thoroughly at the scientific and societal perspectives of 
drug combination therapy as a means of combating drug 
resistance. As a first step, the scientific community will 
need to strengthen its assessment of appropriate usage, 
defining parameters for deciding which antimicrobials 
are effective in which areas of the world and useful at 
various levels of the healthcare system. The WHO Global 
Development and Stewardship Framework to Combat 
AMR can facilitate progress in this area together with a 
broader public–private engagement.
Finance
Strategies for making progress towards UHC emphasise 
measures to reduce the financial burden of healthcare 
on poor families. Out-of-pocket payments by individuals 
account for a substantial share of total health expend-
iture in a number of countries. They account for 70% 
of total health expenditure in India, and 70% of those 
payments are for drugs. This section focuses on ways that 
strategies for health finance can influence the use of anti-
microbials.
Many countries are increasing the contribution of 
government and health insurance to total health expen-
diture. If a scheme covers outpatient treatment of infec-
tions, it can substantially reduce the financial barriers to 
access to antimicrobial treatment. This is likely to lead to 
increases in the use of these drugs. This can save lives, but 
it can also lead to unnecessary use. This is a particularly 
high risk if the payment of health workers and the facility 
is linked to the volume of drugs they supply. Measures to 
reduce the cost of antimicrobials to patients need to be 
complemented by actions to ensure that these drugs are 
used appropriately by providing treatment guidelines, 
monitoring the quality of treatment, altering the pattern 
of incentives and supporting surveillance for AMR.
In countries where the poor rely heavily on informal 
providers of healthcare and drugs, it may take a long 
time to provide universal health insurance. Other 
measures will be needed to increase access to effec-
tive treatment. One option is for government, donor 
agencies and philanthropic organisations to reduce the 
cost of antimicrobials through more effective procure-
ment and/or by supplying drugs at a subsidised price. 
This might involve programmes to address common 
infections such as childhood and postnatal infections. 
The provision of subsidised antimicrobials would 
need to be linked to measures to ensure they are used 
appropriately.
The Global Action Plan on AMR calls for substan-
tial investments to combat AMR. A large proportion of 
these funds is likely to be allocated to the development 
of new antimicrobials, on the understanding that the 
use of any new drugs would be severely limited. This is 
unlikely to command support unless there is also invest-
ment in measures to increase access to effective treat-
ment of common infections. A combined investment 
strategy would address the factors that contribute to the 
emergence of resistance and acknowledge the need to 
ensure universal access to antimicrobials. That would 
increase the likelihood of winning wide political 
support. The effective implementation of this kind of 
strategy would depend on effective partnerships, as 
highlighted below. Without high levels of support, it 
may be difficult to prevent the production and commer-
cial use of new antimicrobials that are developed.
Partnerships
The achievement of progress towards UHC, while 
containing AMR, hinges on partnerships and coalition 
building. The activities of many stakeholders need to 
be aligned to the cause of providing access to appropriate 
antimicrobial treatment while reducing the risk of resistance. 
For a partnership to survive, each partner must believe 
that the benefits it derives from the effort of creating 
and maintaining it outweigh the potential losses from 
the constraints to pursuing its narrow interests. The 
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Table 1 Health system attributes and universal health coverage actions for addressing AMR
Health system attributes Actions for addressing AMR
Equity Reduce the burden of infectious disease among the poor by strengthening basic public health 
and prevention
Ensure access to appropriate antibiotics at an affordable cost, including by the poor
Ensure that measures aimed at reducing inappropriate use of antimicrobials do not interfere 
with access to them by the poor
Quality Regulate the quality of antimicrobials
Include AMR in medical curriculum and training programmes
Ensure that guidelines for treatment of infections take into account surveillance findings
Ensure that advice on antimicrobial use provided to healthcare workers and through 
advertisements reflects best-practice guidelines and acknowledges the threat of AMR
Increase access to low-cost diagnostic technologies for more accurate diagnosis
Efficiency Alter financial incentives that encourage overuse of antimicrobials
Reduce need for expensive treatment of infections with resistant organisms
Accountability Provide information on surveillance findings
Provide information on appropriate treatment for different infections
Sustainability and resilience Strengthen public health services and immunisation to reduce exposure to infections
Establish partnerships for management of antimicrobials
Carry out awareness and educational campaigns to change understanding of healthcare 
workers and the population on appropriate use of antimicrobials
Invest in research and development (R&D) of new drugs and in new approaches for providing 
effective treatment of common infections
Source: WHO. Antimicrobial Resistance in the Asia Pacific region: a development Agenda. 2017. WHO, Geneva.
AMR, antimicrobial resistance.
way a partnership balances the interests of the different 
members reflects the governance arrangements put 
in place and the relative power of the different part-
ners.22 Powerful actors such as pharmaceutical compa-
nies, especially the generic manufacturers who supply 
cheap medicines to private providers, have not been 
sufficiently persuaded that entering into partnerships 
aiming to limit sales of antibiotics is in their economic 
interest.
A sustained effort to induce system-wide changes 
in the use of antibiotics will require informed and 
committed coalitions at national, regional and global 
levels. Partnerships between the public and private 
sector, and the formal and informal sector, are espe-
cially important. Collaboration is also needed between 
those responsible for health prevention and heath 
provision. This will require a one-health approach that 
extends beyond the boundaries of the government 
health system. It will be important to ensure that the 
perspectives of poor and powerless people are taken 
into account so they are not required to bear unneces-
sary risks of treatment failure or high costs and so that 
no one is left behind. One aim of this kind of coali-
tion would be to establish basic standards of conduct 
for healthcare workers and for drug companies that 
emphasise the needs of patients and of the community. 
This may require new business and financial models to 
address perverse incentives. These coalitions will need 
to be able to monitor progress in ensuring access to 
treatment and reducing inappropriate use of antibi-
otics. The government will need to build its capacity to 
play an effective role in this process.
conclusIons: A systeMs APProAcH to AddressIng AMr
Table 1 illustrates how the actions described above can 
be integrated into the routine functioning of a health 
system, through linking them to core health system 
attributes and dimensions of health system strengthening 
towards UHC.
Simple interventions can have unintended conse-
quences. For example, measures to restrict access to 
antibiotics to a doctor’s prescription may reduce equity 
by decreasing access to treatment by the poor. Also, 
strategies that focus disproportionately on one aspect 
of the system, such as ensuring access to treatment of 
infections, will have limited impact if basic public health 
and disease prevention are neglected. The different 
health system attributes are highly interdependent and 
stewardship requires a multilevel systems perspective.23
Actions that are not based on an understanding of 
the interdependencies relevant to antibiotic supply 
and use may have relatively little impact. For example, 
qualified doctors often blame patients or the informal 
sector for inappropriate antibiotic use, when their own 
practices are frequently no better. ‘Patient demand’ is 
often noted to be a major factor in influencing inap-
propriate prescribing by healthcare workers. However, 
observations of clinical interactions have not always 
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confirmed this.24 Also this demand has been stimulated 
by the many public campaigns to convince people of 
the value of antibiotics. Other factors that influence the 
decisions to use antibiotics need to be considered, such 
as perverse financial incentives and inadequate under-
standing of appropriate treatment guidelines.
There are no blueprints for implementing multi-
level changes at scale in complex and rapidly changing 
contexts. These changes include measures to address 
immediate problems, such as inadequate access to 
treatment and problems with drug quality, and the 
longer term need to change attitudes and create more 
effective mechanisms to govern and manage antimicro-
bial use. It is important to employ a learning approach 
to the management of this kind of system change.
National action plans need to take into account 
regional and global interdependencies. Dense trans-
portation links, the movement of large quantities of 
goods and people, the behaviour of international phar-
maceutical companies and international media influ-
ence national systems. Countries with larger national 
incomes and higher levels of economic and social 
organisation have a stake in the success of measures by 
relatively low-income countries to reduce their burden 
of infectious diseases and increase access to effective 
treatment. Measures to address AMR will need to be 
built on the foundation of strong regional and global 
agreements on actions that address the concerns of all 
countries and all social groups through a whole-of-so-
ciety approach.
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